Previously, BioMoti announced on 18th August 2016, the signature of a conditional Share Purchase Agreement to be acquired by Physiomics Plc (AIM: PYC). However, due to not meeting the main condition, Physiomics Plc raising a minimum of £1 million in a placing, the acquisition will not complete.

Physiomics Plc did complete a placing of £555 thousand and will focus their efforts on growing their core modelling and simulation business at this point.

BioMoti will continue to pursue opportunities to develop its very promising cancer therapeutic technology through investments, partnerships and other suitable means.

For more details, please click to read the Physiomics Plc regulatory update